ALK and neuroblastoma: Aberrant activation of ALK has also been reported in the childhood cancer neuroblastoma (NB), where both germline and somatic point mutations, predominantly in the kinase domain of the receptor, have been reported (Caren et al, 2008; Chen et al, 2008; George et al, 2008; Janoueix‐Lerosey et al, 2008; Mosse et al, 2008).